- Home
- TGI vs CNTA Comparison
TGI vs CNTA Comparison
Compare TGI & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGI
- CNTA
- Stock Information
- Founded
- TGI 1993
- CNTA 2020
- Country
- TGI United States
- CNTA United Kingdom
- Employees
- TGI N/A
- CNTA N/A
- Industry
- TGI Aerospace
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- TGI Industrials
- CNTA Health Care
- Exchange
- TGI Nasdaq
- CNTA Nasdaq
- Market Cap
- TGI 2.0B
- CNTA 2.2B
- IPO Year
- TGI 1996
- CNTA 2021
- Fundamental
- Price
- TGI $24.70
- CNTA $12.30
- Analyst Decision
- TGI Hold
- CNTA Strong Buy
- Analyst Count
- TGI 8
- CNTA 9
- Target Price
- TGI $20.63
- CNTA $25.63
- AVG Volume (30 Days)
- TGI 2.4M
- CNTA 1.2M
- Earning Date
- TGI 05-22-2025
- CNTA 05-12-2025
- Dividend Yield
- TGI N/A
- CNTA N/A
- EPS Growth
- TGI N/A
- CNTA N/A
- EPS
- TGI 7.25
- CNTA N/A
- Revenue
- TGI $1,242,654,000.00
- CNTA N/A
- Revenue This Year
- TGI $3.60
- CNTA N/A
- Revenue Next Year
- TGI $10.85
- CNTA N/A
- P/E Ratio
- TGI $144.89
- CNTA N/A
- Revenue Growth
- TGI 7.23
- CNTA N/A
- 52 Week Low
- TGI $11.01
- CNTA $7.75
- 52 Week High
- TGI $25.55
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- TGI 43.71
- CNTA 40.90
- Support Level
- TGI $24.23
- CNTA $11.50
- Resistance Level
- TGI $25.00
- CNTA $12.82
- Average True Range (ATR)
- TGI 0.34
- CNTA 1.21
- MACD
- TGI -0.08
- CNTA 0.03
- Stochastic Oscillator
- TGI 39.29
- CNTA 50.95
About TGI Triumph Group Inc.
Triumph Group Inc designs and manufactures a broad portfolio of aerostructures, aircraft components, and systems for the aviation industry. It serves a customer base of players in the commercial, business, and military markets. The company operates under two operating segments: Systems and Support, which derives key revenue and designs, develops, and supports proprietary components; and Interiors, which supplies commercial and regional manufacturers with aircraft interior systems.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.